SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021
We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and de...
Saved in:
| Published in | iScience Vol. 26; no. 4; p. 106222 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
21.04.2023
Elsevier The Author(s) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2589-0042 2589-0042 |
| DOI | 10.1016/j.isci.2023.106222 |
Cover
| Abstract | We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign.
[Display omitted]
•Immunity in France before the vaccination campaign was too low to achieve herd immunity•The infection/hospitalization ratio increased with age•4 months after seroconversion, modeling estimated antibody decay to be ∼50%•IgG seroprevalence was lower in individuals with O blood type than A, B, and AB
Immunology; Immune response; Virology |
|---|---|
| AbstractList | We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign. We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n=32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p=0.003) than in A, B and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modelling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign. We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign. [Display omitted] •Immunity in France before the vaccination campaign was too low to achieve herd immunity•The infection/hospitalization ratio increased with age•4 months after seroconversion, modeling estimated antibody decay to be ∼50%•IgG seroprevalence was lower in individuals with O blood type than A, B, and AB Immunology; Immune response; Virology We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign.We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign. |
| ArticleNumber | 106222 |
| Author | Nurtop, Elif Gallian, Pierre Pastorino, Boris Isnard, Christine Brisbarre, Nadège Hozé, Nathanaël Saba Villarroel, Paola Mariela Cauchemez, Simon Morel, Pascal de Lamballerie, Xavier Richard, Pascale |
| Author_xml | – sequence: 1 givenname: Pierre surname: Gallian fullname: Gallian, Pierre email: pierre.gallian@efs.sante.fr organization: Établissement Français du Sang, La Plaine Saint Denis 93218, France – sequence: 2 givenname: Nathanaël surname: Hozé fullname: Hozé, Nathanaël organization: Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015 Paris, France – sequence: 3 givenname: Nadège surname: Brisbarre fullname: Brisbarre, Nadège organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France – sequence: 4 givenname: Paola Mariela surname: Saba Villarroel fullname: Saba Villarroel, Paola Mariela organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France – sequence: 5 givenname: Elif orcidid: 0000-0002-9715-8394 surname: Nurtop fullname: Nurtop, Elif organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France – sequence: 6 givenname: Christine surname: Isnard fullname: Isnard, Christine organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France – sequence: 7 givenname: Boris surname: Pastorino fullname: Pastorino, Boris organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France – sequence: 8 givenname: Pascale surname: Richard fullname: Richard, Pascale organization: Établissement Français du Sang, La Plaine Saint Denis 93218, France – sequence: 9 givenname: Pascal surname: Morel fullname: Morel, Pascal organization: Établissement Français du Sang, La Plaine Saint Denis 93218, France – sequence: 10 givenname: Simon surname: Cauchemez fullname: Cauchemez, Simon organization: Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015 Paris, France – sequence: 11 givenname: Xavier surname: de Lamballerie fullname: de Lamballerie, Xavier organization: Unité des Virus Émergents (UVE: Aix-Marseille University - IRD 190 - Inserm 1207), 13005 Marseille, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36818722$$D View this record in MEDLINE/PubMed https://hal.science/hal-04007375$$DView record in HAL |
| BookMark | eNp9Ul1r2zAUNaNj7br-gT0MPW4wZ_qyJcEYhLC2gcBg3fYqZPnaUXCsTHIM_feT6660fSgISVydc66kc95mJ73vIcveE7wgmJRfdgsXrVtQTFkqlJTSV9kZLaTKMeb05NH-NLuIcYcxpmlwVb7JTlkpiRSUnmXtzfLnTb7yf3KK1u0VihD8IcBoOugtoHgMI9xG5HpUdd7XqPa9DxFV0PgAaNgCGo21rjeD8z2yZn8wru0_o8tgJn66Hs7TRN5lrxvTRbi4X8-z35fff62u882Pq_VqucltURRDLgwYIeuyqI0RjbBYSqtkYyrOJJOV5LQwpKmkpLVQggpmJeWyYYQYUYKp2Xm2nnVrb3b6ENzehFvtjdN3BR9abcLgbAda1QWjjONGgeHCiqriQtWUpE6NtEQlrW-z1uFY7aG20A_BdE9En570bqtbP2qlGGYSJ4FPs8D2Ge16udFTDXOMBRPFSBL2432z4P8eIQ56nwyGrjM9-GPUVAjFOKdEJuiHx_d6UP7vagLQGWCDjzFA8wAhWE_p0Ts9pUdP6dFzehJJPiNZN9zZmt7mupepX2cqJGdHB0EnxJSf2gWwQ_p69xL9H7MW3GM |
| CitedBy_id | crossref_primary_10_1080_00365513_2024_2361279 |
| Cites_doi | 10.1016/S2468-2667(21)00064-5 10.3201/eid2803.211885 10.1016/j.idnow.2020.12.007 10.1093/cid/ciaa1150 10.1038/s41467-020-19481-7 10.1111/trf.16693 10.2807/1560-7917.ES.2020.25.10.2000180 10.1016/j.jcv.2021.105045 10.3390/v13020160 10.1001/jama.2020.18598 10.1016/j.tmrv.2021.07.003 10.1371/journal.pcbi.1009436 10.1111/joim.13304 10.1001/jama.2021.15161 10.1016/S2666-7568(21)00253-1 10.1016/j.cmi.2021.01.030 10.1016/S2213-2600(20)30117-X 10.1159/000515258 10.1093/ije/dyab110 10.1016/j.antiviral.2020.104880 10.1016/j.ijid.2020.12.025 10.1093/infdis/jiab375 10.1136/bmjopen-2020-045425 10.1093/cid/ciab537 10.1007/s15010-021-01639-0 10.2807/1560-7917.ES.2020.25.28.2001285 10.1177/2047487320922370 10.1093/infdis/jiab566 |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s) 2023 The Author(s). Attribution - NonCommercial - NoDerivatives 2023 The Author(s) 2023 |
| Copyright_xml | – notice: 2023 The Author(s) – notice: 2023 The Author(s). – notice: Attribution - NonCommercial - NoDerivatives – notice: 2023 The Author(s) 2023 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1016/j.isci.2023.106222 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2589-0042 |
| ExternalDocumentID | oai_doaj_org_article_9d532340f9ea47c7bb479d21383f8c19 PMC9930380 oai_HAL_hal_04007375v1 36818722 10_1016_j_isci_2023_106222 S2589004223002997 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G 6I. AAEDW AAFTH AALRI AAMRU AAXUO AAYWO ABMAC ACVFH ADBBV ADCNI ADVLN AEUPX AEXQZ AFPUW AFTJW AIGII AITUG AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS FDB GROUPED_DOAJ HYE M41 OK1 ROL RPM SSZ AAYXX CITATION EJD NPM 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c555t-7aea78d65daa7f7c088c98fab43838b8425a1fb882d797273c8248f311a76ead3 |
| IEDL.DBID | DOA |
| ISSN | 2589-0042 |
| IngestDate | Wed Aug 27 01:28:26 EDT 2025 Thu Aug 21 18:38:07 EDT 2025 Thu Sep 18 06:20:42 EDT 2025 Fri Jul 11 06:20:34 EDT 2025 Mon Jul 21 06:02:13 EDT 2025 Thu Apr 24 22:52:25 EDT 2025 Tue Jul 01 04:47:21 EDT 2025 Sat Jun 14 16:53:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Immunology Immune response Virology |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2023 The Author(s). Attribution - NonCommercial - NoDerivatives: http://creativecommons.org/licenses/by-nc-nd Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c555t-7aea78d65daa7f7c088c98fab43838b8425a1fb882d797273c8248f311a76ead3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC9930380 equally contributed |
| ORCID | 0000-0002-9715-8394 0000-0001-9186-4549 0000-0002-3310-5808 0000-0001-7895-2720 |
| OpenAccessLink | https://doaj.org/article/9d532340f9ea47c7bb479d21383f8c19 |
| PMID | 36818722 |
| PQID | 2779344218 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9d532340f9ea47c7bb479d21383f8c19 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9930380 hal_primary_oai_HAL_hal_04007375v1 proquest_miscellaneous_2779344218 pubmed_primary_36818722 crossref_primary_10_1016_j_isci_2023_106222 crossref_citationtrail_10_1016_j_isci_2023_106222 elsevier_sciencedirect_doi_10_1016_j_isci_2023_106222 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-21 |
| PublicationDateYYYYMMDD | 2023-04-21 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | iScience |
| PublicationTitleAlternate | iScience |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier The Author(s) |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: The Author(s) |
| References | Kaspersen, Hindhede, Boldsen, Mikkelsen, Vestergaard, Berthelsen, Moustsen-Helms, Holm, Nilsson, Sækmose (bib13) 2022; 225 Dodd, Xu, Stramer (bib29) 2020; 324 Grant, Dub, Andrianou, Nohynek, Wilder-Smith, Pezzotti, Fontanet (bib31) 2021; 11 Stone, Grebe, Sulaeman, Di Germanio, Dave, Kelly, Biggerstaff, Crews, Tran, Jerome (bib9) 2022; 28 Lapidus, Paireau, Levy-Bruhl, de Lamballerie, Severi, Touvier, Zins, Cauchemez, Carrat (bib8) 2021; 51 Weidner, Nunhofer, Jungbauer, Hoeggerl, Grüner, Grabmer, Zimmermann, Rohde, Laner-Plamberger (bib15) 2021; 49 Jeffery-Smith, Rowland, Patel, Whitaker, Iyanger, Williams, Giddings, Thompson, Zavala, Aiano (bib3) 2021; 2 Dai (bib22) 2020; 27 Carrat, de Lamballerie, Rahib, Blanché, Lapidus, Artaud, Kab, Renuy, Szabo de Edelenyi, Meyer (bib7) 2021; 50 Vassallo, Dumont, Bravo, Hazegh, Kamel (bib26) 2021; 35 Slot, Hogema, Reusken, Reimerink, Molier, Karregat, IJlst, Novotný, van Lier, Zaaijer (bib10) 2020; 11 Cai (bib20) 2020; 8 Cassaniti, Percivalle, Sarasini, Cambiè, Vecchio Nepita, Maserati, Ferrari, Corcione, Di Martino, Bonetti (bib16) 2021; 27 Zhao, Yang, Huang, Li, Gu, Lu, Zhang, Liu, Liu, Liu (bib28) 2021; 73 Cheng, Cheng, Chui, Lau, Chan, Ng, Sung, Wong (bib21) 2005; 293 Pendu, Breiman, Rocher, Dion, Ruvoën-Clouet (bib23) 2021; 13 Chen, Flegg, White, Aguas (bib30) 2021; 17 Di Stefano, Sarno, Faleo, Farhan Mohamed, Lipsi, De Nittis, Bruno, De Feo, Granato, Corso (bib17) 2021; 144 Fischer, Knabbe, Vollmer (bib11) 2020; 25 Warszawski, Bajos, Meyer, de Lamballerie, Seng, Beaumont, Slama, Hisbergues, Rahib, Lydié (bib6) 2020; 1167 Deleers, Breiman, Daubie, Maggetto, Barreau, Besse, Clémenceau, Ruvoën-Clouet, Fils, Maillart (bib27) 2021; 104 Castro Dopico, Muschiol, Christian, Hanke, Sheward, Grinberg, Rorbach, Bogdanovic, Mcinerney, Allander (bib18) 2021; 290 Pelleau, Woudenberg, Rosado, Donnadieu, Garcia, Obadia, Gardais, Elgharbawy, Velay, Gonzalez (bib4) 2021; 224 Gallian, Pastorino, Morel, Chiaroni, Ninove, de Lamballerie (bib24) 2020; 181 Butler, Coyne, Pomeroy, Williams, Holder, Carterson, Field, Waters, O'Flaherty (bib25) 2022; 146 Hozé, Paireau, Lapidus, Tran Kiem, Salje, Severi, Touvier, Zins, de Lamballerie, Lévy-Bruhl (bib5) 2021; 6 bib1 Jones, Stone, Sulaeman, Fink, Dave, Levy, Di Germanio, Green, Notari, Saa (bib12) 2021; 326 Stone, Di Germanio, Wright, Sulaeman, Dave, Fink, Notari, Green, Strauss, Kessler (bib14) 2022; 74 Valenti, Pelusi, Cherubini, Bianco, Ronzoni, Uceda Renteria, Coluccio, Berzuini, Lombardi, Terranova (bib19) 2021; 61 Mizumoto, Kagaya, Zarebski, Chowell (bib2) 2020; 25 Chen (10.1016/j.isci.2023.106222_bib30) 2021; 17 Kaspersen (10.1016/j.isci.2023.106222_bib13) 2022; 225 Zhao (10.1016/j.isci.2023.106222_bib28) 2021; 73 Jeffery-Smith (10.1016/j.isci.2023.106222_bib3) 2021; 2 Stone (10.1016/j.isci.2023.106222_bib14) 2022; 74 Deleers (10.1016/j.isci.2023.106222_bib27) 2021; 104 Cheng (10.1016/j.isci.2023.106222_bib21) 2005; 293 Butler (10.1016/j.isci.2023.106222_bib25) 2022; 146 Lapidus (10.1016/j.isci.2023.106222_bib8) 2021; 51 Weidner (10.1016/j.isci.2023.106222_bib15) 2021; 49 Fischer (10.1016/j.isci.2023.106222_bib11) 2020; 25 Castro Dopico (10.1016/j.isci.2023.106222_bib18) 2021; 290 Valenti (10.1016/j.isci.2023.106222_bib19) 2021; 61 Pendu (10.1016/j.isci.2023.106222_bib23) 2021; 13 Warszawski (10.1016/j.isci.2023.106222_bib6) 2020; 1167 Di Stefano (10.1016/j.isci.2023.106222_bib17) 2021; 144 Grant (10.1016/j.isci.2023.106222_bib31) 2021; 11 Gallian (10.1016/j.isci.2023.106222_bib24) 2020; 181 Carrat (10.1016/j.isci.2023.106222_bib7) 2021; 50 Jones (10.1016/j.isci.2023.106222_bib12) 2021; 326 Pelleau (10.1016/j.isci.2023.106222_bib4) 2021; 224 Mizumoto (10.1016/j.isci.2023.106222_bib2) 2020; 25 Cai (10.1016/j.isci.2023.106222_bib20) 2020; 8 Stone (10.1016/j.isci.2023.106222_bib9) 2022; 28 Slot (10.1016/j.isci.2023.106222_bib10) 2020; 11 Dai (10.1016/j.isci.2023.106222_bib22) 2020; 27 Vassallo (10.1016/j.isci.2023.106222_bib26) 2021; 35 Cassaniti (10.1016/j.isci.2023.106222_bib16) 2021; 27 Hozé (10.1016/j.isci.2023.106222_bib5) 2021; 6 Dodd (10.1016/j.isci.2023.106222_bib29) 2020; 324 |
| References_xml | – volume: 225 start-page: 219 year: 2022 end-page: 228 ident: bib13 article-title: Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark publication-title: J. Infect. Dis. – volume: 27 start-page: 1436 year: 2020 end-page: 1437 ident: bib22 article-title: ABO blood group predisposes to COVID-19 severity and cardiovascular diseases publication-title: Eur. J. Prev. Cardiol. – volume: 2 start-page: e811 year: 2021 end-page: e819 ident: bib3 article-title: Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England publication-title: Lancet. Healthy Longev. – volume: 51 start-page: 380 year: 2021 end-page: 382 ident: bib8 article-title: Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population publication-title: Infect. Dis. Now – volume: 17 start-page: e1009436 year: 2021 ident: bib30 article-title: Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys publication-title: PLoS Comput. Biol. – volume: 293 start-page: 1450 year: 2005 end-page: 1451 ident: bib21 article-title: ABO blood group and susceptibility to severe acute respiratory syndrome publication-title: JAMA – volume: 50 start-page: 1458 year: 2021 end-page: 1472 ident: bib7 article-title: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study publication-title: Int. J. Epidemiol. – volume: 290 start-page: 666 year: 2021 end-page: 676 ident: bib18 article-title: Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden publication-title: J. Intern. Med. – volume: 61 start-page: 3381 year: 2021 end-page: 3389 ident: bib19 article-title: Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors publication-title: Transfusion – volume: 8 start-page: e20 year: 2020 ident: bib20 article-title: Sex difference and smoking predisposition in patients with COVID-19 publication-title: Lancet Respir. Med. – volume: 13 start-page: 160 year: 2021 ident: bib23 article-title: ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? A reasoned review of available data publication-title: Viruses – volume: 11 start-page: 5744 year: 2020 ident: bib10 article-title: Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in The Netherlands publication-title: Nat. Commun. – ident: bib1 article-title: (2022). COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins university (JHU) – volume: 27 start-page: 914.e1 year: 2021 end-page: 914.e4 ident: bib16 article-title: Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area publication-title: Clin. Microbiol. Infect. – volume: 181 start-page: 104880 year: 2020 ident: bib24 article-title: Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors publication-title: Antiviral Res. – volume: 49 start-page: 1187 year: 2021 end-page: 1194 ident: bib15 article-title: Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors publication-title: Infection – volume: 6 start-page: e408 year: 2021 end-page: e415 ident: bib5 article-title: Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study publication-title: Lancet Public Health – volume: 11 start-page: e045425 year: 2021 ident: bib31 article-title: SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review publication-title: BMJ Open – volume: 74 start-page: 871 year: 2022 end-page: 881 ident: bib14 article-title: Use of US blood donors for national serosurveillance of severe acute respiratory syndrome coronavirus 2 antibodies: basis for an expanded national donor serosurveillance program publication-title: Clin. Infect. Dis. – volume: 35 start-page: 8 year: 2021 end-page: 15 ident: bib26 article-title: Progression and predictors of SARS-CoV-2 antibody seroreactivity in US blood donors publication-title: Transfus. Med. Rev. – volume: 1167 start-page: 1 year: 2020 end-page: 6 ident: bib6 article-title: En mai 2020, 4,5 % de la population en France métropolitaine a développé des anticorps contre le SARS-CoV-2. Etudes et Résultats publication-title: Direction de la Recherche, des études, de l’évaluation et des statistiques – volume: 144 start-page: 580 year: 2021 end-page: 584 ident: bib17 article-title: Low prevalence of antibodies to SARS-CoV-2 and undetectable viral load in seropositive blood donors from south-eastern Italy publication-title: Acta Haematol. – volume: 73 start-page: 328 year: 2021 end-page: 331 ident: bib28 article-title: Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility publication-title: Clin. Infect. Dis. – volume: 224 start-page: 1489 year: 2021 end-page: 1499 ident: bib4 article-title: Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection publication-title: J. Infect. Dis. – volume: 104 start-page: 242 year: 2021 end-page: 249 ident: bib27 article-title: Covid-19 and blood groups: ABO antibody levels may also matter publication-title: Int. J. Infect. Dis. – volume: 28 start-page: 672 year: 2022 end-page: 683 ident: bib9 article-title: Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications publication-title: Emerg. Infect. Dis. – volume: 25 start-page: 2001285 year: 2020 ident: bib11 article-title: SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 publication-title: Euro Surveill. – volume: 25 start-page: 2000180 year: 2020 ident: bib2 article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship publication-title: Euro Surveill. – volume: 326 start-page: 1400 year: 2021 end-page: 1409 ident: bib12 article-title: Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations publication-title: JAMA – volume: 146 start-page: 105045 year: 2022 ident: bib25 article-title: Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection publication-title: J. Clin. Virol. – volume: 324 start-page: 1677 year: 2020 end-page: 1679 ident: bib29 article-title: Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US, June-August 2020 publication-title: JAMA – volume: 6 start-page: e408 year: 2021 ident: 10.1016/j.isci.2023.106222_bib5 article-title: Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study publication-title: Lancet Public Health doi: 10.1016/S2468-2667(21)00064-5 – volume: 28 start-page: 672 year: 2022 ident: 10.1016/j.isci.2023.106222_bib9 article-title: Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2803.211885 – volume: 51 start-page: 380 year: 2021 ident: 10.1016/j.isci.2023.106222_bib8 article-title: Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population publication-title: Infect. Dis. Now doi: 10.1016/j.idnow.2020.12.007 – volume: 73 start-page: 328 year: 2021 ident: 10.1016/j.isci.2023.106222_bib28 article-title: Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa1150 – volume: 11 start-page: 5744 year: 2020 ident: 10.1016/j.isci.2023.106222_bib10 article-title: Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in The Netherlands publication-title: Nat. Commun. doi: 10.1038/s41467-020-19481-7 – volume: 1167 start-page: 1 year: 2020 ident: 10.1016/j.isci.2023.106222_bib6 article-title: En mai 2020, 4,5 % de la population en France métropolitaine a développé des anticorps contre le SARS-CoV-2. Etudes et Résultats publication-title: Direction de la Recherche, des études, de l’évaluation et des statistiques – volume: 61 start-page: 3381 year: 2021 ident: 10.1016/j.isci.2023.106222_bib19 article-title: Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors publication-title: Transfusion doi: 10.1111/trf.16693 – volume: 25 start-page: 2000180 year: 2020 ident: 10.1016/j.isci.2023.106222_bib2 article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2020.25.10.2000180 – volume: 146 start-page: 105045 year: 2022 ident: 10.1016/j.isci.2023.106222_bib25 article-title: Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2021.105045 – volume: 13 start-page: 160 year: 2021 ident: 10.1016/j.isci.2023.106222_bib23 article-title: ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? A reasoned review of available data publication-title: Viruses doi: 10.3390/v13020160 – volume: 324 start-page: 1677 year: 2020 ident: 10.1016/j.isci.2023.106222_bib29 article-title: Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US, June-August 2020 publication-title: JAMA doi: 10.1001/jama.2020.18598 – volume: 35 start-page: 8 year: 2021 ident: 10.1016/j.isci.2023.106222_bib26 article-title: Progression and predictors of SARS-CoV-2 antibody seroreactivity in US blood donors publication-title: Transfus. Med. Rev. doi: 10.1016/j.tmrv.2021.07.003 – volume: 17 start-page: e1009436 year: 2021 ident: 10.1016/j.isci.2023.106222_bib30 article-title: Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1009436 – volume: 290 start-page: 666 year: 2021 ident: 10.1016/j.isci.2023.106222_bib18 article-title: Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden publication-title: J. Intern. Med. doi: 10.1111/joim.13304 – volume: 326 start-page: 1400 year: 2021 ident: 10.1016/j.isci.2023.106222_bib12 article-title: Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations publication-title: JAMA doi: 10.1001/jama.2021.15161 – volume: 2 start-page: e811 year: 2021 ident: 10.1016/j.isci.2023.106222_bib3 article-title: Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England publication-title: Lancet. Healthy Longev. doi: 10.1016/S2666-7568(21)00253-1 – volume: 27 start-page: 914.e1 year: 2021 ident: 10.1016/j.isci.2023.106222_bib16 article-title: Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2021.01.030 – volume: 8 start-page: e20 year: 2020 ident: 10.1016/j.isci.2023.106222_bib20 article-title: Sex difference and smoking predisposition in patients with COVID-19 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30117-X – volume: 144 start-page: 580 year: 2021 ident: 10.1016/j.isci.2023.106222_bib17 article-title: Low prevalence of antibodies to SARS-CoV-2 and undetectable viral load in seropositive blood donors from south-eastern Italy publication-title: Acta Haematol. doi: 10.1159/000515258 – volume: 50 start-page: 1458 year: 2021 ident: 10.1016/j.isci.2023.106222_bib7 article-title: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study publication-title: Int. J. Epidemiol. doi: 10.1093/ije/dyab110 – volume: 181 start-page: 104880 year: 2020 ident: 10.1016/j.isci.2023.106222_bib24 article-title: Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2020.104880 – volume: 104 start-page: 242 year: 2021 ident: 10.1016/j.isci.2023.106222_bib27 article-title: Covid-19 and blood groups: ABO antibody levels may also matter publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2020.12.025 – volume: 224 start-page: 1489 year: 2021 ident: 10.1016/j.isci.2023.106222_bib4 article-title: Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab375 – volume: 11 start-page: e045425 year: 2021 ident: 10.1016/j.isci.2023.106222_bib31 article-title: SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review publication-title: BMJ Open doi: 10.1136/bmjopen-2020-045425 – volume: 293 start-page: 1450 year: 2005 ident: 10.1016/j.isci.2023.106222_bib21 article-title: ABO blood group and susceptibility to severe acute respiratory syndrome publication-title: JAMA – volume: 74 start-page: 871 year: 2022 ident: 10.1016/j.isci.2023.106222_bib14 article-title: Use of US blood donors for national serosurveillance of severe acute respiratory syndrome coronavirus 2 antibodies: basis for an expanded national donor serosurveillance program publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciab537 – volume: 49 start-page: 1187 year: 2021 ident: 10.1016/j.isci.2023.106222_bib15 article-title: Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors publication-title: Infection doi: 10.1007/s15010-021-01639-0 – volume: 25 start-page: 2001285 year: 2020 ident: 10.1016/j.isci.2023.106222_bib11 article-title: SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2020.25.28.2001285 – volume: 27 start-page: 1436 year: 2020 ident: 10.1016/j.isci.2023.106222_bib22 article-title: ABO blood group predisposes to COVID-19 severity and cardiovascular diseases publication-title: Eur. J. Prev. Cardiol. doi: 10.1177/2047487320922370 – volume: 225 start-page: 219 year: 2022 ident: 10.1016/j.isci.2023.106222_bib13 article-title: Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab566 |
| SSID | ssj0002002496 |
| Score | 2.2283702 |
| Snippet | We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical... We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical... We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n=32605), from March-2020 to January-2021. A mathematical... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 106222 |
| SubjectTerms | Immune response Immunology Life Sciences Microbiology and Parasitology Vaccinology Virology |
| Title | SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021 |
| URI | https://dx.doi.org/10.1016/j.isci.2023.106222 https://www.ncbi.nlm.nih.gov/pubmed/36818722 https://www.proquest.com/docview/2779344218 https://hal.science/hal-04007375 https://pubmed.ncbi.nlm.nih.gov/PMC9930380 https://doaj.org/article/9d532340f9ea47c7bb479d21383f8c19 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagJy6IileAIoO4QSDxI06OS0VZEOJAKerN8ivbVChB-_r9zNjZ1QakcuGSg5PYiufz-HM8_oaQV8JJFYQMufK2yEVlmtwEcIaWV8Hz0nNjY4Ds12p-IT5fysuDVF8YE5bkgVPHvWu85IyLom2CEcopa4VqPCthZdXWLgp-sqIpDhZT13F7DaXwYmY5iTFBAM3xxEwK7sITr28xczgUVIyxyawUxfsnk9PtK4yS_JuC_hlJeTA1nd0jd0dOSWfpW47JrdDfJ4vz2bfz_HT4kTP6afGRAtQw4QkAC8cyXW2WWzAi7XoaY9epH_phuaI2AIsNFGgh3RrnuvSzkDrUZewW_RsaM3EEynBBCJfyAbk4-_D9dJ6PWRVyJ6Vc58oEo2pfSW-MapUDN-OaujUWRUtri9typmwtMG-vGmQ3rmaibnlZGlUB7vhDctQPfXhMqBXgtq1tgJIFYaWvAwvWKw-kLkBhlZFy16vajZLjmPnip97Fll1rtIRGS-hkiYy83r_zKwlu3Pj0ezTW_kkUy44FACE9Qkj_C0IZkTtT65F3JD4BVXU3Nv4ScDFpez77orEMXaPiSm7LjLzYwUbDyMXtGNOHYbPSTIFvFAI4VkYeJRjt6-IVECmFTagJwCaNTe_03VVUBwfCWfC6ePI_euYpuYPfi7tnrHxGjtbLTTgBEra2z-N4-w2d2Cql |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+IgG+seroprevalence+surveys+in+blood+donors+before+the+vaccination+campaign%2C+France+2020-2021&rft.jtitle=iScience&rft.au=Gallian%2C+Pierre&rft.au=Hoz%C3%A9%2C+Nathana%C3%ABl&rft.au=Brisbarre%2C+Nad%C3%A8ge&rft.au=Saba+Villarroel%2C+Paola+Mariela&rft.date=2023-04-21&rft.eissn=2589-0042&rft.volume=26&rft.issue=4&rft.spage=106222&rft_id=info:doi/10.1016%2Fj.isci.2023.106222&rft_id=info%3Apmid%2F36818722&rft.externalDocID=36818722 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-0042&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-0042&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-0042&client=summon |